Safety of experimental HN2302 for autoimmune diseases
Part of Immune system & allergy, Skin clinical trials.
This trial tests an experimental medicine called HN2302 in people with certain autoimmune diseases like lupus or scleroderma. The goal is to see if it is safe and if it can help reduce disease activity, which might improve symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be an adult between 18 and 69 years old.
- You need a diagnosis of systemic lupus erythematosus (SLE) or systemic sclerosis (SSc) by a doctor.
- Your overall health (heart, liver, kidneys, blood, etc.) must be within a safe range for the study.
- If you are able to have children, you must agree to use effective birth control for 12 months after the study drug infusion.
- You must not have had a major organ transplant (like heart, lung, liver, kidney or bone marrow) in the past.
- You must not have active infections (like hepatitis B, C, HIV, CMV, syphilis) or have received an mRNA-LNP drug in the last 2 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new mRNA treatment called HN2301 for people with autoimmune diseases like lupus, scleroderma, or rheumatoid arthritis. It aims to see if the treatment is safe and helps control the disease.
This trial tests a new cell therapy called YTS109 for people with severe autoimmune diseases that have not responded to standard treatments. The goal is to see if it can reset the immune system and reduce disease activity in conditions like lupus, Sjögren's syndrome, and others.
This study tests a new investigational drug (called ATG-201) for people with autoimmune diseases. It aims to see if the drug is safe and how it works in the body.
This study tests a new drug called HBM7020 to see if it is safe and how well it is absorbed by the body. It is for healthy people and people with certain autoimmune diseases like lupus, scleroderma, rheumatoid arthritis, or Sjögren's disease.
This early-phase trial tests a new drug called TI-0032-III for people with several autoimmune diseases that haven't gotten better with standard treatments. It aims to see if the drug can safely reduce disease activity and offer a new option for people who have few choices left.
This study is testing an experimental medicine called PF-08154225 to see if it can help treat several autoimmune conditions, including rheumatoid arthritis, lupus, and related disorders. It might reduce disease activity or symptoms in people who have not found relief from other treatments.
Hear when a new Systemic Lupus Erythematosus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.